CinCor Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CINC research report →
Range $30 – $73
Price Chart
About the company
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders.
- CEO
- Marc M. P. de Garidel
- IPO
- 2022
- Employees
- 19
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on CINC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.27B
- P/E
- -20.46
- PEG
- 0.23
- P/S
- 0.00
- P/B
- -16.15
- EV/EBITDA
- -32.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 110.68%
- ROIC
- -34.11%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-42,510,406
- Net Income
- $-50,347,433-126.2%
- EPS
- $-1.42-49.5%
- OCF Growth
- -77.3%
- FCF Growth
- -77.3%
- 52W High
- $43.15
- 52W Low
- $10.53
- 50D MA
- $25.59
- 200D MA
- $25.14
- Beta
- 0.00
- RSI (14)
- 69
- Avg Volume
- 625.75K
No earnings-call transcripts are available for CINC yet.
- Free Float
- 40.9%
- Shares Outstanding
- 43.76M
- Float Shares
- 17.91M
of shares held by institutions
89 13F filers
Buy/sell ratio 0.18. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Amalgamated Financial Corp. | 2.27K | ▲ 2.27K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 23 | 5AM Partners VI, LLC | other | 496,323 |
| Feb 24, 23 | HEALY JAMES | other | 9,803 |
| Feb 24, 23 | HEALY JAMES | sell | 19,608 |
| Nov 28, 22 | HEALY JAMES | sell | 6,000 |
| Feb 24, 23 | HEALY JAMES | other | 6,073,949 |
| Feb 24, 23 | Freeman Mason | other | 2,494 |
| Jun 10, 22 | Freeman Mason | sell | 6 |
| Feb 24, 23 | Freeman Mason | other | 100 |
| Feb 24, 23 | Freeman Mason | sell | 40,000 |
| Feb 24, 23 | Freeman Mason | sell | 30,178 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CINC coverage
Recent articles, reports, and earnings notes.
No research on CINC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CINC report →There's a Lot to Love About Mineralys' Valentine's Day IPO
marketbeat.com · Feb 13
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.
prnewswire.com · Jan 9
Why Is CinCor (CINC) Stock Up 138% Today?
investorplace.com · Jan 9
AstraZeneca to acquire CinCor for US$1.8bn
proactiveinvestors.co.uk · Jan 9
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
barrons.com · Jan 9
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
reuters.com · Jan 9
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
247wallst.com · Dec 13
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
zacks.com · Nov 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.